RxDoctor Payments Data

Adam Wallace, MD

Pain Medicine · Tulsa, OKNPI 1518129733

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,709 of the $7,954 with a category attached, or 84.4%. It is spread thinly across 44 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,655 and has fallen 63.0% since, to $982 in 2025.

$7,954in general payments, 2019–2025

Across 297 payments — averaging $26.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$2K
  • Vertiflex, Inc.$1K
  • Boston Scientific$886
  • Collegium Pharmaceutical, Inc.$658
  • Abbott$344
  • Medtronic$305
  • plus $2K from 38 others

What the payments were for

  • Speaking & faculty fees$631%
  • Travel & lodging$1,18115%
  • Food & beverage$6,70984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,954 in reported general payments places this provider in the 70th percentile of 68 pain medicine providers in Oklahoma.

See all pain medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$270,387
Medicare patients
542
Services billed
6,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl273$217,731
Buprenorphine290$63,800
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,655$44,521
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,109$32,023
ZtlidoLidocaine13$10,245
Gabapentin587$7,195
Pregabalin440$7,044
MovantikNaloxegol Oxalate19$7,027
Acetaminophen-CodeineAcetaminophen With Codeine271$6,835
BelsomraSuvorexant11$4,946
Tramadol Hcl ErTramadol Hcl100$4,710
Oxycodone Hcl233$4,302
Lidocaine41$4,083
Tramadol Hcl441$3,800
DayvigoLemborexant13$3,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$658$217,731273 claims
Scilex Pharmaceuticals Inc.Ztlido$265$10,24513 claims
Eisai Inc.Dayvigo$33$3,80013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 68 pain medicine providers in Oklahoma.

Other pain medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →